This company has been acquired
Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
G1 Therapeutics Yönetim
Yönetim kriter kontrolleri 2/4
G1 Therapeutics' CEO is Jack Bailey, appointed in Jan 2021, has a tenure of 3.67 years. total yearly compensation is $3.25M, comprised of 24.5% salary and 75.5% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth $1.40M. The average tenure of the management team and the board of directors is 3.7 years and 6 years respectively.
Anahtar bilgiler
Jack Bailey
İcra Kurulu Başkanı
US$3.3m
Toplam tazminat
| CEO maaş yüzdesi | 24.5% |
| CEO görev süresi | 3.7yrs |
| CEO sahipliği | 0.4% |
| Yönetim ortalama görev süresi | 3.7yrs |
| Yönetim Kurulu ortalama görev süresi | 6yrs |
Son yönetim güncellemeleri
Recent updates
There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise
Jul 26
G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty
Jun 24Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why
Jun 07Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
May 28G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 04Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
Mar 22Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge
Feb 27Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?
Feb 06G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry
Jan 04Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
Jun 08New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)
May 08The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts
Nov 04G1 Therapeutics: Catalysts Stacking
Oct 20G1 Therapeutics: Building A Franchise
Sep 29Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)
Aug 04G1 Therapeutics Q2 2022 Earnings Preview
Aug 02G1 Therapeutics: Take Advantage Of The November Data
Jul 22CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$45m |
| Mar 31 2024 | n/a | n/a | -US$31m |
| Dec 31 2023 | US$3m | US$795k | -US$48m |
| Sep 30 2023 | n/a | n/a | -US$71m |
| Jun 30 2023 | n/a | n/a | -US$78m |
| Mar 31 2023 | n/a | n/a | -US$126m |
| Dec 31 2022 | US$3m | US$764k | -US$148m |
| Sep 30 2022 | n/a | n/a | -US$154m |
| Jun 30 2022 | n/a | n/a | -US$171m |
| Mar 31 2022 | n/a | n/a | -US$171m |
| Dec 31 2021 | US$9m | US$735k | -US$148m |
| Sep 30 2021 | n/a | n/a | -US$134m |
| Jun 30 2021 | n/a | n/a | -US$103m |
| Mar 31 2021 | n/a | n/a | -US$95m |
| Dec 31 2020 | US$2m | n/a | -US$99m |
Tazminat ve Piyasa: Jack's total compensation ($USD3.25M) is above average for companies of similar size in the US market ($USD2.42M).
Tazminat ve Kazançlar: Jack's compensation has increased whilst the company is unprofitable.
CEO
Jack Bailey (59 yo)
3.7yrs
Görev süresi
US$3,250,658
Tazminat
Mr. John E. Bailey, also known as Jack, Jr. has been Director at G1 Therapeutics, Inc. since March 12, 2020. He serves as President and Chief Executive Officer at G1 Therapeutics Inc. since January 1, 2021...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 3.7yrs | US$3.25m | 0.37% $ 1.4m | |
| Chief Medical Officer | 10.2yrs | US$1.11m | 0.17% $ 625.3k | |
| Chief Business Officer | 5.2yrs | US$1.17m | 0.049% $ 186.1k | |
| Chief Financial Officer | 1.5yrs | Veri yok | 0.037% $ 138.2k | |
| Chief Operating Officer | 5.7yrs | US$2.75m | 0.040% $ 151.2k | |
| Vice President of Investor Relations & Corporate Communications | 3.7yrs | Veri yok | Veri yok | |
| Chief Legal & People Officer | 1.3yrs | Veri yok | 0.013% $ 49.0k | |
| Vice President of Marketing | no data | Veri yok | Veri yok | |
| Chief Commercial Officer | 3.1yrs | US$3.39m | 0.027% $ 101.8k | |
| Senior Director of Investor Relations & Corporate Communications | no data | Veri yok | Veri yok |
3.7yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: GTHX's management team is considered experienced (3.7 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 4.5yrs | US$3.25m | 0.37% $ 1.4m | |
| Member of Clinical Advisory Board | no data | US$456.29k | Veri yok | |
| Independent Director | 9yrs | US$172.85k | 0.35% $ 1.3m | |
| Scientific & Clinical Advisor | no data | Veri yok | Veri yok | |
| Scientific & Clinical Advisor | no data | Veri yok | Veri yok | |
| Independent Director | 6.3yrs | US$162.85k | 0.030% $ 113.6k | |
| Independent Chairman of the Board | 6yrs | US$195.35k | 0.027% $ 102.9k | |
| Scientific & Clinical Advisor | no data | Veri yok | Veri yok | |
| Director | 2.2yrs | US$135.35k | 0% $ 0 | |
| Co-Founder & Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Scientific & Clinical Advisor | no data | Veri yok | Veri yok | |
| Scientific & Clinical Advisor | no data | Veri yok | Veri yok |
6.0yrs
Ortalama Görev Süresi
67yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: GTHX's board of directors are considered experienced (6 years average tenure).